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A B S T R A C T
Background: To this day, empirical data suggests that zinc has important roles in matrix synthesis, bone turn-
over, and mineralization and its beneﬁcial eﬀects on bone could be mediated through diﬀerent mechanisms. The
inﬂuence of zinc on bone turnover could be facilitated via regulating RANKL/RANK/OPG pathway in bone
tissue. Therefore, the aim of the study was to conduct a review to investigate the possible eﬀect of the zinc
mediated bone remodeling via RANKL/RANK/OPG pathway.
Methods: A comprehensive systematic search was performed in MEDLINE/PubMed, Cochrane Library, SCOPUS,
and Google Scholar to explore the studies investigating the eﬀect of zinc as a bone remodeling factor via RANKL/
RANK/OPG pathway regulation. Subsequently, the details of the pathway and the impact of zinc supplements on
RANKL/RANK/OPG pathway regulation were discussed.
Results: The pathway could play an important role in bone remodeling and any imbalance between RANKL/
RANK/OPG components could lead to extreme bone resorption. Although the outcomes of some studies are
equivocal, it is evident that zinc possesses protective properties against bone loss by regulating the RANKL/
RANK/OPG pathway. There are several experiments where zinc supplementation resulted in upregulation of
OPG expression or decreases RANKL level. However, the results of some studies oppose this.
Conclusion: It is likely that suﬃcient zinc intake will elicit positive eﬀects on bone health by RANKL/RANK/OPG
regulation. Although the outcomes of a few studies are equivocal, it seems that zinc can exert the protective
properties against bone loss by suppressing osteoclastogenesis via downregulation of RANKL/RANK.
Additionally, there are several experiments where zinc supplementation resulted in upregulation of OPG ex-
pression. However, the results of limited studies oppose this. Therefore, aside from the positive role zinc pos-
sesses in preserving bone mass, further eﬀects of zinc in RANKL/RANK/OPG system requires further animal/
human studies.
1. Introduction
The skeleton is responsible for enduring mechanical load in the
body and plays some important roles in inﬂammation, hormonal and
mineral challenges in the body. Further, it is suggested that the skeleton
may inﬂuence the parenchymal function of organs such as the kidney
and pancreas by secreting some agents [1]. As a connective tissue, the
skeleton has 4 types of cells including osteoblasts, osteoclasts, osteo-
cytes, and bone lining cells. Bone tissue is perpetually in turnover;
where osteoblasts control the formation of bone, and osteoclast activ-
ities lead to bones resorption [2]. Bone mass is mainly comprised of
minerals in varying types and combinations, such as hydroxyapatite,
proteins including collagen and noncollagenous proteins, water and etc.
each of these components is inﬂuencing by gender, disease, age, and
site [3]. There are many risk factors that may deleteriously impact
skeleton health, including low calcium level, vitamin D deﬁciency, se-
dentary lifestyle, hyperthyroid and hypothyroid, high blood pressure,
high-stress level, hysterectomy, and postmenopause [4]. Some of the
disorders that mainly involve the skeleton include osteoporosis, rickets,
osteomalacia, renal osteodystrophy, Paget's disease and malignancy of
bone [5]. When bone mass reduced, some harmful change appear in
bone structure [6]. Further, bone health is weakened as people age,
especially in developing countries [7]. In Britain, 1 in 5 men and 1 in 2
women over ﬁfty years old, suﬀer from at least one fracture during their
lifetime [8]. Based on recent ﬁndings, over 200 million people suﬀer
from osteoporosis, globally [9], with most fractures occurring in the
hips and forearm [10]. Although the actual eﬀects of pharmacological
agents on bone disorders is not yet clear; there is a burgeoning ﬁeld of
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research dedicated to elucidating potential interactions. Some of the
most common drugs in bone diseases include bisphosphonates, deno-
sumab, estrogen, PTH peptide, Strontium ranelate, DKK1, and scler-
ostin antibodies, and calcium-sensing receptor antagonists [11]. On the
other side, there are some medications that may have negative inﬂu-
ences on bone health, including thyroid medications [12], anti-diabetic
drugs [13], proton pump inhibitors [14], and antidepressants [15]. In
order to preserve bone health, suﬃcient and persistent intake of some
nutrients such as vitamin D, vitamin K, vitamin A, calcium, magnesium,
ﬂuoride, phosphorus, copper, potassium and zinc are necessary [16].
With a proper nutritional strategy, it is conceivable that reductions in
bone loss, especially at early ages when the genome still has time for
epigenetic changing, maybe feasible [7].
Zinc is one of the important minerals for growth and bone health
preservation; whilst deﬁciency in zinc has multiple complications, in-
cluding diarrhea, alopecia immune dysfunction, growth retardation,
and cognitive impairment. Aging, bone resorption and post-menopause
all act to reduce zinc quantities in bone [17–19]. Zinc is required for
protein and DNA synthesis in the skeleton [20,21], whilst zinc deﬁ-
ciency leads to a major reduction in collagen synthesis and turnover
[21]. It is also a stimulant for osteoblastic cells and suppresses osteo-
clast activity [22]. Empirical data suggests that zinc has important roles
in matrix synthesis, mammalian system and probably in bone miner-
alization [23], and its protective and beneﬁcial eﬀects on bone could be
mediated through cell proliferation, increasing collagen production,
and stimulation alkaline phosphatase activity [24]. Furthermore, in-
ﬂuence on bone turnover could be facilitated via zinc regulating
RANKL/RANK/OPG pathway in bone tissue [25]. Zinc could inhibit the
osteoclastogenesis which is induced by RANKL (receptor activator of
NF-KB ligand) [19]. The pathway and its components are part of the
tumor necrosis factor (TNF) superfamily, which could play an im-
portant role in bone remodeling. RANKL/RANK axis control osteoclasts
formation and activity [26]. Moreover, these are identifying as key
indicators on bone turnover in bone-related pathological situations.
OPG, as the RANKL`s decoy receptor, plays a bone protective role by
binding to RANKL and prevention of bone resorption [26]. The im-
balance between RANKL and OPG could lead to extreme bone resorp-
tion [26].
Although, there are several studies depicting the beneﬁcial eﬀects of
zinc on bone health; the current evidence is not enough to approve the
bone protective role of zinc supplementation in respect to RANKL/
RANK/OPG balance. Therefore, the aim of this study was to review the
eﬀect of zinc supplements on regulation of RANKL/RANK/OPG axis
which will help the future studies to focus and assist in developing
potent strategies for treating patients with bone disorders.
A comprehensive systematic search was performed in MEDLINE/
PubMed, Cochrane Library, SCOPUS, and Google Scholar to explore the
studies investigating the eﬀect of zinc as a bone remodeling factor via
RANKL/RANK/OPG pathway regulation. We comprehensively searched
through the databases for in vitro and in vivo studies that investigated
the eﬀect of zinc on bone health via regulation of RANKL/RANK/OPG
pathway. Additionally, we tried to ﬁnd more related studies with
manual reference list checking. We used both MeSH term and free-text
in titles/abstracts as follow: ("Zinc"[Mesh] OR “Zinc supplement*”)
AND (“"Bone and Bones"[Mesh]) AND ("RANK Ligand"[Mesh] OR
“RANKL” OR “RANK” OR “Osteoprotegrin” OR “OPG”. We did not re-
strict the searches according to their languages or the type of study. The
studies for literature review were selected if they met the following
criteria: 1) using any form of zinc as single or multi-component sup-
plement, 2) studies in which they investigated the role of zinc in
RANKL/RANK/OPG modulation regarding the bone cells. We primarily
searched and identiﬁed the eligible in-vivo and in-vitro studies by
electronic searching and manual searching of reference lists of eligible
studies. By secondary screening, ineligible articles were excluded due to
duplication in investigated databases, and being irrelevant to the pur-
pose of the current review. Subsequently, the details of the pathway and
the impact of zinc supplements on RANKL/RANK/OPG pathway reg-
ulation were discussed.
2. Zinc and bone health
There are multiple trace minerals which participate in bone meta-
bolism, such as copper, magnesium, ﬂuoride, and zinc [27]. Low level
of copper and magnesium in serum can lead to depletion in BMD
[28,29]. Zinc is one of the most essential trace elements for the body
[30], is an important cofactor for DNA and RNA synthesize enzymes,
and is a major stimulant for growth [31], and could interfere in che-
mical catalysis or indirectly participate in protection of protein struc-
ture [32]. Zinc food sources include; red meat, poultry, shellﬁsh, seeds,
nuts, dairy, and beans [33], and a reported 2 billion people suﬀer from
zinc deﬁciency, necessitating supplementation with zinc [34]. Zinc
supplements have varying side eﬀects and diﬀerent absorption rates
based on their composition, with zinc sulfate, zinc picolinate, zinc
acetate, zinc gluconate, zinc orotate, and zinc citrate are available zin
supplements in market [35–37]. Zinc deﬁciency can result in, for ex-
ample, alopecia, dermatitis, loss of appetite, immune system dysfunc-
tion, and growth retardation [38,39]. Conversely, zinc toxicity includes
issues such as nausea, vomiting, lethargy, fatigue and epigastric pain
[40]. There is about 2–3 gr zinc in the human body and approximately
0.1% of this amount is excreted which and thus must be replenished
through dietary intake [31]. A great amount of total body zinc esides in
the skeleton [41]. It has been shown that zinc has an essential role in
bone metabolism and mineralization, for instance, in osteoblasts, zinc
could activate aminoacyl-tRNA synthetase and also prohibit osteoclasts
from bone resorption. Zinc increases protein synthetase which helps in
the protection of bone health [42]. It has been suggested that urinary
zinc level may be employed as a convenient marker for bone loss re-
cognition [43]. Zinc could result in signiﬁcant upregulation in alkaline
phosphatase activity which is important for bone calciﬁcation and plays
an important role as a biochemical marker for bone development
[44,45], zinc ﬁnger transcription factors, TRAF6-inhibitory zinc ﬁnger
protein and Schnurri-3 [46]. Aging, bone unloading and post-meno-
pause may facilitate a reduction in bone zinc quantities [25]. Since
almost 800 μg per gram of creatinine is expelled in urine in women with
osteoporosis, urinary zinc is utilized as a marker for bone resorption in
postmenopausal women [47]. It has been shown that zinc receptors are
necessary for the normal matrix and cells in bone. Antecedent work has
indicated that zinc and its receptor could change the expression of some
enzymes and adjust collagen production in the skeleton [48]. Further-
more, zinc activity in the bone could aﬀect both proliferation and dif-
ferentiation of osteoblast-like cells [49]. Oral intake of zinc supple-
ments could help to protect bone from resorption in various conditions,
such as aluminum toxicity, Ca deﬁciency, vitamin D deﬁciency, es-
trogen deﬁciency, diabetes, and arthritis. So, administration of zinc
compounds could add to bone loss protection and prevention protocols
[50]. Zinc deﬁciency contributes to many types of abnormalities in
bones in fetal and postnatal terms [50]. In young animals, where zinc
deﬁciency is identiﬁed, they face to reduction in somatomedin (IGF-I)
synthesis and growth problem [51,52]. A zinc ﬁnger transcription
factor, Osterix (Osx), is expressed in, almost, all growing bones; the
genetical role of Osx in bone formation and bone homeostasis is well
known and operates gene collection for diﬀerentiation of pre-osteo-
blasts to osteoblasts and osteocytes [53]. Zinc chelated with β-alanyl-L-
histidine results in the formation of β-Alanyl-L-histidine zinc (AHZ),
which can stimulate bone formation more than zinc sulfate. In addition,
zinc acexamate is another compound which has identical eﬀects to AHZ
in bone formation, and is comparable with other bone regulator factors
[25]. Some studies indicate zinc may elicit positive inﬂuences on the
healing of bone fractures [54,55]. The ability of zinc to suppress os-
teoclastogenesis is likely because of its inhibitory eﬀects on RANKL.
Moreover, it may conceivably prevent the pre-osteoclast signaling
pathway which is related to the RANK/RANKL system [50].
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3. RANKL/RANK/OPG pathway
Nf-kB is a superfamily, where constituent proteins take part in the
signaling pathways [56]. Some of the Nf-kB family members are con-
trolled in inﬂammatory and neoplastic conditions that might be moti-
vated by proinﬂammatory factors [57]. Also, elimination of some of
these agents may leads to unwanted bone development [58]. One of the
most important systems of this family is RANKL/RANK/OPG signaling
pathway, is regarded an important system for immunity and is essential
for bone homeostasis [59]. RANK or receptor activator of NF-kB is a
transmembrane protein contain 3 subunits. It originally discovered in
mature osteoblasts, dendric cells and osteoclast precursors (OCP) [60].
A deletion mutation in RANK which reported in transgenic mice iden-
tiﬁed the signiﬁcance of RANK in osteoclastogenesis [61]. RANKL (re-
ceptor activator of NF-kB ligand also known as osteoclast diﬀerentia-
tion factor) is a homotrimeric protein, part of TNF superfamily, and is
encoded by TNFSF11 gene [61]. RANKL is mainly expressed by acti-
vated T cells, osteoblasts, ﬁbroblasts and stromal cells [62], and ex-
pressed in mammary gland epithelial cells during pregnancy, causing
hyperplasia during lactation [63]; in addition, it is expressed in some
tumor cells and may control their proliferation [64]. Overexpression of
RANKL has been observed in various diseases such as arthritis rheu-
matoid and psoriatic arthritis [65,66]. RANKL is regulatable by dif-
ferent agents such as glucocorticoids, TNF-a, TGF-b, IL-1 LSP. this
protein has the facility to bind to both RANK and OPG [59]. OPG (the
soluble decoy receptor osteoprotegerin) encoded by TNF receptor fa-
mily member 11B gene (TNFRSF11B) [67], and has been detected
during an investigation designed for TNFR (tumor necrosis factor re-
ceptor) related molecules [68]. OPG mRNA has been found in many cell
types, including skin, liver, heart, lung and bone marrow stromal cells
[69,70]. The main responsibility of OPG is inhibition of RANK matching
with RANKL [67]; moreover, OPG could bind to TRAIL (TNF-related
apoptosis-inducing ligand) to prevent TRAIL-induced apoptosis [71]. In
addition to RANKL and TRAIL, OPG could bind to some other agents
like glycosaminoglycans (GAGs), von Willebrand Factor, Factor VIII-
von Willebrand Factor complex, and syndecan-1 [72]. The RANKL/
RANK/OPG system has important roles in various organs and condi-
tions such as bone modeling and remodeling [61], cancer cells [73],
pregnancy [63], immune system [74], and cardiovascular disease [75].
4. RANKL/RANK/OPG in bone
Osteoclasts are regarded the most important cells in bone resorp-
tion, where osteoclast precursors have the potential to maturate via
stimulation of some factors. Among these factors, there are 2 cytokines;
M-CSF, a cytokine that secreted by several types of cells like stromal
cells and osteoblast, and receptor activator of NF-kB, part of RANKL/
RANK/OPG system [76]. RANKL/RANK/OPG system is active in var-
ious conditions including vascular calciﬁcation [77], cancer [78], bone
modeling a remodeling, and some genetic disorders [79]. The discovery
of RANKL/RANK/OPG system in bone turnover in the late 1990s is
regarded as an important ﬁnding for developing bone health [80].
The interaction between RANK and its ligand (RANKL), on the ex-
ternal layer of OPCs (osteoclast precursor cells), results in maturation of
these cells and turning to osteoclasts. Osteoclasts which migrated to the
bone surface, secretion of some enzyme like cathepsin K and tartrate-
resistant acid phosphatase, and acceleration of bone resorption.
Osteoprotegerin expressed by bone stromal cells and osteoblasts, play
role as decoy receptor for RANKL and prevents the binding of RANK
and RANKL with its higher aﬃnity to RANKL [81]. The OPG-RANKL
ratio is less than 1 in postmenopausal women [49], with some studies
reported that blocking RANKL leads to an increase in OPG level, and
could noticeably reduce bone loss during lactation [82]. The timing of
RANK expression and its link to RANKL is a serious issue in osteoclas-
togenesis [83]. Both RANKL and RANK must be present in order for
osteoclastogenesis to happen, where, in mice unable to express RANK
and RANKL, they suﬀered from osteopetrosis [84]. However, in mice
with OPG deﬁciency, osteoporosis occurred earlier than normal mice,
attributed to the high number of osteoclasts diﬀerentiation [85]. OPG
overexpression in animal models has resulted in deep osteoporosis to
the extent that a total loss in osteoblasts happen [86]. Rheumatoid
arthritis is an inﬂammatory disease that can weaken bone in numerous
ways. RANKL is one of the factors that have expected to take part in RA
bone problems. Suppressing RANKL and other agents like TNF re-
present a promising treatment for minimizing RA Complications [87].
Paget disease is another bone disorder with the Interference of RANKL-
RANK in its development [88]. Paget disease of bone is mainly identi-
ﬁed by central bone resorption and increased osteoclast activity. In
PDB, RANKL expression and its sensitivity increases which leads to
more bone problems [89]. Recent studies regarding bone cancer have
investigated signaling systems in this disease; RANKL and RANK most
probably have developing eﬀects on bone tumors while OPG could be
decreasing cancer-induced bone pain [73,90]. Tumor cells upregulating
RANKL expression in bone stromal cells through increasing IL-6, IL-1B,
TNF, epidermal growth factor and PTH-related peptide (PTH-rP), so
osteoclastogenesis increased [91]. In this case, using the anti-RANKL
treatment such as anti-RANKL medication (like denosumab) or gene
therapy might have signiﬁcant eﬀects in cancer development [92].
Furthermore, recent investigations has suggested that mechanical
pressure could lead osteocytes to recall osteoclasts to the bone resorp-
tion sites via regulating RANKL synthesis in osteoblasts [61].
5. Zinc and RANKL/RANK/OPG in bone
The aim of this study was to review the eﬀect of zinc on RANKL/
RANK/OPG pathway in the skeleton. In a recent animal study, zinc
supplementation in ovariectomized (OVX) and diabetic (T1DM) rats
resulted in increases in OPG expression that led to marked decreases in
RANKL/OPG ratio [93]. Another study indicated zinc antioxidant
property might prevent RANKL/RANK/OPG disbalance in Cd-induced
rats [94], whilst an in vitro study on mouse marrow cells indicated that
adding zinc sulfate led to inhibition in RANKL-induced osteoclast-like
cells [95]. Additionally, zinc sulfate could increase OPG mRNA ex-
pression after 24–48 h in cultured cells, based on an in-vitro study [96].
The reports of a study regarding the eﬀects of zinc demonstrated that as
a result of using a zinc-free diet, the expression of RANK reduced and
the level of RANKL and OPG did not change. Overall [97], indicated
that zinc deﬁciency could decrease both osteoclastogenesis and osteo-
blastogenesis [97]. The result of an in vitro investigation regarding M-
CSF and RANKL highlighted that zinc can prevent osteoclasts diﬀer-
entiation by the dose-depending reduction in RANKL [98]. In a recent
study, the eﬀects of Puerarin and zinc on ovariectomized rat (OVX)
bones demonstrated co-supplementation decreased RANKL and in-
creased OPG and OPN (osteopontin) [99]. It was further demonstrated
that RANKL worked through indirect Ca2+ signaling mediation [100].
Based on a rat study, adequate consumption of zinc likely does not
aﬀect osteoblastogenesis, but it may reduce osteoclastogenesis via
suppression of RANK expression through prevention of ROS (reactive
oxygen species) production and ERK (extracellular signal-regulated
kinase) activation [101]. A recent study has shown, in the group of mice
in the TNF inﬂammatory environment, with a higher concentration on
Zn, RANKL expression is meaningfully diminished [102]. The eﬀect of
zinc supplementation on diabetic induced bone loss has been in-
vestigated through an animal study, demonstrating that supplementa-
tion can reduce chronic T1DM-induced bone loss by increasing OC
(osteocalcin) and decreasing RANKL and OPG [103]. Also, another
experiment on diabetic rat demonstrated a reduction in RANK expres-
sion via zinc supplementation [104]. In Fong et al, a higher ratio of
RANKL/OPG was reported in a metallothionein knockout (MT -/-)
group and received a lower amount of zinc compared to others [105];
whilst, according to Liang et al, zinc could aﬀect OPG gene expression
in osteoblasts and increasing it [106].
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In contrast to these studies, there are some studies which show
distinct consequences. In a study on male rats that received zinc sup-
plements, it was reported that dietary zinc supplementation upregu-
lated RANKL expression in bone by TNF-α and IL-1β; this resulted in
bone loss without any speciﬁc change in the size of bones [107]. It was
shown in another animal study that suppressing ZIP4 (Zinc transporter
ZIP4) could up-regulate bone mineral density and down-regulate bone
turnover in mice with pancreatic cancer via RANKL-RANK system
[108]; whilst some work has reported that zinc-modiﬁed titanium (EZ)
aﬀects osteoblasts diﬀerentiation but no signiﬁcant changes in OPG and
RANKL levels are observed [109] (Table 1) (Fig. 1).
6. Conclusion
In conclusion, it is likely that suﬃcient zinc intake will elicit posi-
tive eﬀects on bone health by RANKL/RANK/OPG regulation. Although
the outcomes of a few studies are equivocal, it seems that zinc can exert
the protective properties against bone loss by suppressing osteoclasto-
genesis via downregulation of RANKL/RANK. Additionally, there are
several experiments where zinc supplementation resulted in upregula-
tion of OPG expression. However, the results of limited studies oppose
this. Therefore, aside from the positive role zinc possesses in preserving
bone mass, further eﬀects of zinc in RANKL/RANK/OPG system
Table 1
Summary of the reviewed studies, describing the eﬀects of Zn on RANKL/RANK/OPG pathway in skeleton. RANK (receptor activator of Nf-kB), RANKL (receptor
activator of NF-kB ligand), OPG (osteoprotegerin) and OVX (ovariectomized), STZ (streptozotocine).
Intervention Time Species Outcome Reference
Zinc supplement 90 days OVX/T1DM rats ↓ RANKL/OPG [93]
Zinc supplement 6 months Cadmium induced male rats ↓ sRANKL [94]
↓ RANKL/OPG
Zinc sulfate 7 days Mouse marrow cells (in vitro) ↓ RANKL [95]
Zinc sulfate 3 days Osteoblastic cells (in vitro) ↑ OPG [96]
Zinc deﬁciency 3 weeks Female rats ↓ RANK [97]
zinc 4 days Mice (in vitro) ↓ RANKL [98]
Zinc+ puerarin 12 weeks OVX rats ↓ RANKL [99]
↑ OPG
zinc 1 week Female rats ↓ RANK [101]
zinc 3s days Mice osteoblasts cell (in vitro/inﬂammatory condition) ↓ RANKL [102]
Zinc supplement 90 days Diabetic male rats ↓ RANKL [103]
↓ OPG
Zinc supplement 1 week Diabetic rats (STZ-induced) ↓RANK [104]
zinc 2 days Osteoblastic cells (in vitro) ↑ OPG [106]
Zinc supplement 4 weeks Male rats ↑ RANKL [107]
ZIP4 suppression – Mouse (pancreatic cancer) ↓ RANKL [108]
Zinc-modiﬁed titanium 28 days Human stem cells (in vitro) No change in OPG [109]
RANKL
Fig. 1. Binding between RANKL and RANK lead to maturation in osteoclasts and enhance bone resorption. OPG, as RANKL decoy receptor, would prevent of RANKL/
RANK binding and down-regulating bone loss. Most of the studies have reviewed, indicated a signiﬁcant reduction in RANKL and increment in OPG. RANKL (receptor
activator of NF-kB ligand), RANK (receptor activator of NF-kB), OPG (osteoprotegerin).
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requires further animal/human studies.
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